Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2002

View Archived Issues

Potent dual MMP/TACE inhibitors designed by Novartis

Kagome presents novel hepatoprotectants

PDE inhibitors for use in hypertension, etc.

Piperazine-containing factor Xa inhibitors patented by Cor Therapeutics (Millennium)

Ajinomoto describes factor Xa-inhibitory benzodiazepines

New antimalarial compounds designed by Shionogi R&D team

Schering presents PDE5 inhibitors for erectile dysfunction

Histamine H3 receptor modulators and their use in sleep disorders, etc.

Biovail licenses Metformin GR from DepoMed

Bay-55-9837, a selective VPAC2 agonist, as a potential therapy for type 2 diabetes

First orally active, selective MCH receptor antagonist identified at Takeda

Discovery of potent, selective, nonsteroidal GR antagonists using 3-D pharmacophore design

Cyclophilin-binding compound with immunomodulating, antiasthmatic and antiinflammatory effects

Gastrointestinal safety of NCX-4016 demonstrated in humans

Superior GI tolerance of COX-189 compared to naproxen reported in healthy subjects

Aventis initiates Lovenox trial in patients with acute STEMI

AltaRex announces major directional change

Room-temperature Betaseron launched in U.S. for relapsing-remitting MS

NCX-1015 does not aggravate ischemia/reperfusion-induced gastric injury

Oryx to market and promote Corvert in Canada

Advectus collaborates with U. of N. Carolina on brain tumor drug development

Corixa files request for formal dispute resolution for Bexxar

Genzyme Transgenics announces name change

CPMP issues positive opinion for Xigris in severe sepsis

FDA approves Imagent for ultrasound imaging of the heart

Known antihypertensive drug shows benefit in normotensive rat model of stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...